Abstract
Background
Diabetes affects 10.5% of adults globally, with type 2 diabetes accounting for 90–95% of cases. Achieving optimal glycemic control is crucial yet challenging, particularly with insulin therapy, where 30–50% of patients fail to meet treatment targets. Telemedicine can improve diabetes management but generates vast amounts of data, burdening healthcare professionals. Integrating clinical decision support tools into telemonitoring systems may enhance care efficiency and glycemic control.
Methods
The trial is a multicenter 3-month, three-arm, open-label, randomized controlled trial. The trial aims to enroll 51 participants with type 2 diabetes on insulin therapy. Participants will be divided with a 3:1:1 ratio into telemonitoring with decision support, telemonitoring without decision support, and usual care groups. The study employs connected insulin pens, continuous glucose monitors (CGMs), and activity trackers to enable telemonitoring. Outcomes measured include CGM time in range, HbA1c, hypo- and hyperglycemia incidents, total daily insulin dose, body weight, treatment satisfaction, and adherence.
Discussion
Telemonitoring with decision support has the potential to revolutionize diabetes management by offering personalized treatment suggestions, thereby reducing the burden on healthcare professionals, and improving patient outcomes. This study will provide valuable insights into the effectiveness of such an approach in achieving glycemic control in people with type 2 diabetes on insulin therapy. By evaluating both clinical outcomes and patient and healthcare professionals’ satisfaction, the study aims to contribute to the development of efficient, scalable telehealth solutions for diabetes care.
Trial registration
ClinicalTrials.gov NCT06185296. Registered on December 14, 2023.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Steno Diabetes Center North Denmark, Aalborg, Denmark; Aalborg University, Department of Health Science and Technology, Gistrup, Denmark (GRID:grid.5117.2) (ISNI:0000 0001 0742 471X)
2 Steno Diabetes Center North Denmark, Aalborg, Denmark (GRID:grid.5117.2); Aalborg University, Department of Health Science and Technology, Gistrup, Denmark (GRID:grid.5117.2) (ISNI:0000 0001 0742 471X)
3 Aalborg University, Department of Health Science and Technology, Gistrup, Denmark (GRID:grid.5117.2) (ISNI:0000 0001 0742 471X); Novo Nordisk A/S, Data Science, Bagsværd, Denmark (GRID:grid.425956.9) (ISNI:0000 0004 0391 2646)
4 Aalborg University, Department of Health Science and Technology, Gistrup, Denmark (GRID:grid.5117.2) (ISNI:0000 0001 0742 471X)
5 Zealand University Hospital - Nykøbing Falster, Department of Endocrinology, Nykøbing Falster, Denmark (GRID:grid.476266.7)
6 Novo Nordisk A/S, Companion SaMD Solutions, Bagsværd, Denmark (GRID:grid.425956.9) (ISNI:0000 0004 0391 2646)
7 Novo Nordisk A/S, Medical & Science, Devices and Digital Health, Bagsværd, Denmark (GRID:grid.425956.9) (ISNI:0000 0004 0391 2646)
8 Steno Diabetes Center North Denmark, Aalborg, Denmark (GRID:grid.425956.9); Aalborg University Hospital, Department of Endocrinology, Aalborg, Denmark (GRID:grid.27530.33) (ISNI:0000 0004 0646 7349); Steno Diabetes Center North Denmark, Aalborg, Denmark (GRID:grid.27530.33)
9 Steno Diabetes Center North Denmark, Aalborg, Denmark (GRID:grid.27530.33); Aalborg University, Department of Health Science and Technology, Gistrup, Denmark (GRID:grid.5117.2) (ISNI:0000 0001 0742 471X)